+

WO2005000088A3 - Profil d'expression du cancer du pancreas - Google Patents

Profil d'expression du cancer du pancreas Download PDF

Info

Publication number
WO2005000088A3
WO2005000088A3 PCT/US2004/015642 US2004015642W WO2005000088A3 WO 2005000088 A3 WO2005000088 A3 WO 2005000088A3 US 2004015642 W US2004015642 W US 2004015642W WO 2005000088 A3 WO2005000088 A3 WO 2005000088A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
pancreatic cancer
expression profile
methods
Prior art date
Application number
PCT/US2004/015642
Other languages
English (en)
Other versions
WO2005000088A2 (fr
Inventor
Craig Logsdon
Samir Hanash
Diane Simeone
Original Assignee
Univ Michigan
Craig Logsdon
Samir Hanash
Diane Simeone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Craig Logsdon, Samir Hanash, Diane Simeone filed Critical Univ Michigan
Publication of WO2005000088A2 publication Critical patent/WO2005000088A2/fr
Publication of WO2005000088A3 publication Critical patent/WO2005000088A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et procédés pour le diagnostic du cancer, et notamment les marqueurs du cancer. L'invention concerne plus particulièrement des profils d'expression génique associés aux cancers du pancréas. Les gènes identifiés comme marqueurs du cancer selon les procédés de l'invention conviennent particulièrement au diagnostic et à la caractérisation du cancer du pancréas. L'invention concerne enfin des cibles pour le criblage d'anticancéreux et des applications thérapeutiques.
PCT/US2004/015642 2003-05-19 2004-05-19 Profil d'expression du cancer du pancreas WO2005000088A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47165603P 2003-05-19 2003-05-19
US60/471,656 2003-05-19
US10/848,259 US20050009067A1 (en) 2003-05-19 2004-05-18 Expression profile of pancreatic cancer
US10/848,259 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005000088A2 WO2005000088A2 (fr) 2005-01-06
WO2005000088A3 true WO2005000088A3 (fr) 2005-03-03

Family

ID=33555311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015642 WO2005000088A2 (fr) 2003-05-19 2004-05-19 Profil d'expression du cancer du pancreas

Country Status (2)

Country Link
US (1) US20050009067A1 (fr)
WO (1) WO2005000088A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1204682B1 (fr) * 1999-07-28 2010-11-17 Genentech, Inc. Compositions et procedes de traitement de tumeurs
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
DK1934615T3 (da) * 2005-09-19 2014-07-14 Janssen Diagnostics Llc Fremgangsmåder og materialer til identificering af oprindelsen af et karcinom med ukendt primær oprindelse
AT502722B8 (de) * 2005-10-31 2009-08-15 Bmt Medizinische Forschung Und Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
US7811778B2 (en) * 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
US20080214491A1 (en) * 2007-03-02 2008-09-04 Logsdon Craig D Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
US8252807B2 (en) * 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
US8609437B2 (en) * 2008-01-17 2013-12-17 The Institue for Cancer Research Biomarkers for the diagnosis and treatment of pancreatic cancer
JP2009268665A (ja) * 2008-05-07 2009-11-19 Canon Inc 吸入装置
WO2010021859A1 (fr) * 2008-08-20 2010-02-25 Trustees Of Dartmouth College Compositions et procédés pour le diagnostic et le traitement d'un cancer du canal pancréatique
US20110195924A1 (en) * 2008-10-08 2011-08-11 Logsdon Craig D Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
WO2010148370A1 (fr) * 2009-06-19 2010-12-23 The Regents Of The University Of California 14-3-3sigma en tant que biomarqueur d'un cancer du sein basal
EP2418491A1 (fr) * 2010-08-10 2012-02-15 Bioftalmik, S.L. Procédé pour le diagnostic de la sécheresse oculaire et de la blépharite
WO2012098124A1 (fr) 2011-01-17 2012-07-26 Lykera Biomed Sa Anticorps dirigés contre la protéine s100p pour le traitement et le diagnostic du cancer
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
BR112014002616B1 (pt) * 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
WO2013104103A1 (fr) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 Marqueur de diagnostic et d'indication pour le cancer colorectal
GB2513771B (en) * 2012-01-09 2020-05-27 Suzhou Microdiag Biomedicine Co Ltd Biomarkers for breast cancer predictions and diagnoses
MX361886B (es) 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
WO2014016836A1 (fr) * 2012-07-24 2014-01-30 Given Imaging Ltd. Combinaison de biomarqueurs indiquant une pathologie
CN103911426B (zh) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂s的应用
CN103913575B (zh) * 2013-05-07 2016-02-10 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂s与糖类抗原19-9的联合应用
CN103667444B (zh) * 2013-09-29 2016-01-13 中山大学附属第三医院 一种与胰腺癌相关的肿瘤标记物及其应用
US10604809B2 (en) * 2014-02-04 2020-03-31 Beth Israel Deaconess Medical Center, Inc. Methods and kits for the diagnosis and treatment of pancreatic cancer
FR3025028A1 (fr) * 2014-08-22 2016-02-26 Acobiom Procede pour determiner le pronostic de survie d'un patient atteint d'un cancer du pancreas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142981A1 (en) * 2000-06-14 2002-10-03 Horne Darci T. Gene expression profiles in liver cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142981A1 (en) * 2000-06-14 2002-10-03 Horne Darci T. Gene expression profiles in liver cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRIESS ET AL.: "Identification of disease-specific genes in chronic panchreatitis using DNA array technology", ANNALS OF SURGERY, vol. 234, no. 6, December 2001 (2001-12-01), pages 769 - 779, XP008040967 *
LOBLER ET AL.: "Genes encoding proteins of the extracellular matrix and of the immune system are overexpressed in chronic calcifying pancreatitis", PANCREATOLOGY, vol. 1, no. 134, 2001, XP002982643 *
LOGSDON ET AL.: "Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer", CANCER RESEARCH, vol. 63, 15 May 2003 (2003-05-15), pages 2649 - 2657, XP002982644 *

Also Published As

Publication number Publication date
WO2005000088A2 (fr) 2005-01-06
US20050009067A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2004005891A3 (fr) Profil d'expression du cancer du poumon
WO2003012067A3 (fr) Profil d'expression du cancer de la prostate
WO2005000088A3 (fr) Profil d'expression du cancer du pancreas
WO2007033187A3 (fr) Fusion geniques recurrentes dans le cancer de la prostate
WO2004066941A3 (fr) Profils d'expression destines au cancer du colon et procedes d'utilisation
WO2007134210A3 (fr) Méthodes et compositions destinées au diagnostic et au traitement du cancer
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2002029103A3 (fr) Profils d'expression genetique dans le cancer du foie
WO2005113816A3 (fr) Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
WO2005005601A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer
WO2005111211A8 (fr) Micro-arn et utilisations de ceux-ci
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2008073878A3 (fr) Profil d'expression de gène de carcinomes œsophagiens
WO2006012646A3 (fr) Marqueurs de cancers amacr
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2007058968A3 (fr) Profils d’expression genique et procedes d’utilisation
WO2004098377A3 (fr) Procedes et compositions pour le diagnostic et la therapie de troubles lies a la parkine
WO2005032495A3 (fr) Profils d'expression genique et leurs methodes d'utilisation
WO2008144507A3 (fr) Inhibiteurs de spirooxindole de kinase de l'aurore
WO2004078035A3 (fr) Profiles d'expression pour le cancer du sein et methodes d'utilisation
UA97629C2 (ru) Фармацевтическая композиция, имеющая противоопухолевую активность, и способы
WO2010002779A3 (fr) Naphtyridininones en tant qu’inhibiteurs d’aurora kinase
WO2007059116A3 (fr) Derives de geldanamycine et compositions pharmaceutiques associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载